2 documents found, page 1 of 1
Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ...
Hernández-García, M; García-Castillo, M; Bou, G; Cercenado, E; Delgado-Valverde, M; Oliver, A; Pitart, C; Rodríguez-Lozano, J; Tormo, NImipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the in vitro activity of imipenem-relebactam and comparators against Enterobacterales clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (ICUs) (SUPERIOR, 2016-2017; STEP, 2017-2018). Overall, 747 Enterobacterales isolates (378 Escherichia coli, 252 Klebsiella spp., 64 Enterobacter spp., and 53 o...
Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Entero...
Hernández-García, M; García-Fernández, S; García-Castillo, M; Melo-Cristino, J; Pinto, M; Gonçalves, E; Alves, V; Costa, E; Ramalheira, E; Sancho, LCeftolozane-tazobactam (C/T) is frequently used for infections caused by multidrug-resistant (MDR)-Enterobacterales isolates. Whole-genome sequencing (WGS, Illumina-Hiseq 4000/NovaSeq 6000, OGC, UK) was used to study the population structure, the resistome and the virulome of C/T-susceptible and -resistant MDR Escherichia spp. (n=30) and Klebsiella spp. (n=78) isolates, recovered from lower respiratory, intra-a...